Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 9, Pages 3349
Publisher
MDPI AG
Online
2020-05-11
DOI
10.3390/ijms21093349
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers
- (2020) Bahareh Kashani et al. IMMUNOLOGIC RESEARCH
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer
- (2019) Mitsuji Nagahama et al. MEDICAL ONCOLOGY
- Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review
- (2019) Tatsuo Kanda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
- (2019) Thomas Yau et al. JOURNAL OF HEPATOLOGY
- Multiple roles of microRNA‑146a in immune responses and hepatocellular carcinoma (Review)
- (2019) Huihui Wang et al. Oncology Letters
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
- (2019) et al. JAMA Oncology
- miR‐4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation
- (2019) Amani Ghousein et al. LIVER INTERNATIONAL
- The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
- (2019) Zuzanna Urban-Wojciuk et al. Frontiers in Immunology
- Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities
- (2019) Daiki Taguchi et al. International Journal of Clinical Oncology
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study
- (2018) Theodora Kanni et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
- (2018) Tsukasa SEYA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Combination Cancer Immunotherapy in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
- (2018) Roser Pinyol et al. GUT
- Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
- (2018) Qing Zhang et al. Journal of Immunology Research
- Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
- (2018) Masatoshi Kudo Cancers
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
- (2017) Yuki Haga et al. PLoS One
- Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That Bind Lipopolysaccharide
- (2016) W.-T. Kuo et al. CANCER RESEARCH
- Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention
- (2016) Hai Zou et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- IL-33 regulates the IgA-microbiota axis to restrain IL-1α–dependent colitis and tumorigenesis
- (2016) Ankit Malik et al. JOURNAL OF CLINICAL INVESTIGATION
- Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells
- (2016) Reina Sasaki et al. PLoS One
- Expression of IL-1α correlates with distant metastasis in patients with head and neck squamous cell carcinoma
- (2015) Xavier León et al. Oncotarget
- Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
- (2014) Yasushi Totoki et al. NATURE GENETICS
- Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade
- (2014) X. Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multiple Roles of Toll-Like Receptor 4 in Colorectal Cancer
- (2014) Dhanusha Yesudhas et al. Frontiers in Immunology
- Causal analysis approaches in Ingenuity Pathway Analysis
- (2013) Andreas Krämer et al. BIOINFORMATICS
- Different effects of three interferons L on Toll-like receptor-related gene expression in HepG2 cells
- (2013) Tatsuo Kanda et al. CYTOKINE
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
- (2012) S Hagiwara et al. BRITISH JOURNAL OF CANCER
- Hepatitis C Virus Nonstructural 5A Protein Inhibits Lipopolysaccharide-Mediated Apoptosis of Hepatocytes by Decreasing Expression of Toll-Like Receptor 4
- (2011) Ryo Tamura et al. JOURNAL OF INFECTIOUS DISEASES
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now